ADMA Biologics, Inc. has announced commencement of operations and initiation of donor plasma collections at its newest ADMA BioCenters plasma collection facility located in Goose Creek, South Carolina.
“We are honored to have commemorated the opening of our Goose Creek, South Carolina plasma collection facility with South Carolina Governor, Henry McMaster, to whom we are sincerely grateful for his and his administration’s support. The state’s impressive infrastructure and skilled workforce create a terrific foundation for ADMA to safely collect and process plasma, and we look forward to continuing to grow our operations in the state now and in the coming years. The Governor’s ribbon cutting at our newest plasma collection facility marks the latest achievement in what has been an excellent start to 2021 for ADMA across all of its business units,” said Adam Grossman, President and Chief Executive Officer of ADMA. “ADMA currently has seven plasma collection facilities under its corporate umbrella at various stages of approval and development and remains on track to achieve its stated goal of having 10 or more plasma collection centers in operation by 2024.”
“Securing raw material plasma supply has never been more important than it is today, and we believe the series of recent acquisitions of plasma collection facilities validates this scarcity value. We anticipate that our BioCenters’ expansion strategy will support our goal of generating quarter-over-quarter revenue growth throughout 2021 and beyond, solidify our objective to establish a fully integrated and self-sufficient plasma supply chain, enable ADMA to ensure continuity of product supply to customers and patients and ultimately create significant asset value for our shareholders,” concluded Mr. Grossman.
Pursuant to updated United States Food and Drug Administration (“FDA”) guidance to obtain approval for plasma collection centers, sponsors are now required to collect plasma donations for 3 months prior to submitting a Biologics License Application (“BLA”) filing. Accordingly, ADMA expects to file its BLA for the Goose Creek, S.C. plasma collection facility in approximately 3 months from center opening and anticipates a standard 12-month BLA review period by the FDA. In the meantime, ADMA is permitted to collect plasma donations at this site, and once FDA approved, it can utilize the plasma collected for further use in the manufacturing of life saving therapies.
This new, state-of-the-art plasma collection center features automated registration, high-tech collection equipment designed to shorten the donation process, free Wi-Fi wireless network in the donor collection area, individual flat-screen TVs with cable at each donor station, and highly trained and certified staff who put donor comfort and safety first. At full capacity, the plasma center expects to maintain a staff of up to 50 highly trained healthcare workers.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!